The 60-Day Pipeline: From Funnel to Flow
Why the best sites think in weekly cohorts, not conversion rates
Brandon Li
Breaking the Enrollment Plateau: Why Month 3 Kills Momentum
The dangerous month 3 patient recruitment slump (and how to avoid it)
Gerard Sanacora, Professor at Yale, on glutamate, GABA, and the next era of depression treatment
Brandon Li talks with Dr. Gerard Sanacora, Professor of Psychiatry at Yale, about his journey from molecular physiology to pioneering research on GABA, glutamate, and rapid-acting antidepressants. Gerard shares how a surprising finding in patients undergo
Backing Breakthroughs in Psychedelics
Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine
Joel Raskin, CMO of Arrivo Bio talks about unlocking the future of psychiatry
Brandon Li talks with Joel Raskin, Chief Medical Officer at Arrivo, about his journey from training in psychiatry in Toronto to leading pharmaceutical research in his current role. Joel shares details on SP-624, an Arrivo compound showing promise in treat
Dr. Jerry Rosenbaum & Dr. Sharmin Ghaznavi: Mass General Center on the Neuroscience of Psychedelics
In this episode, Dr. Jerry Rosenbaum and Dr. Sharmin Ghaznavi offer a rare look into academia’s role in the psychedelic renaissance, tracing the origins of Mass General’s Center for the Neuroscience of Psychedelics. They discuss how their shared interest
Spyros Papapetropoulos, CEO of Neuphoria
Spyros Papapetropoulos, a leading neurologist and neuroscientist, joins Power CEO, Brandon Li, to discuss his remarkable career and the transformative work at Neuphoria. Spyros delves into his transition from practicing neurologist to drug development and